Uptake of Dexcom's OTC glucose monitor Stelo outpaces Abbott's Lingo, Citi says
** Brokerage Citi says early uptake of Dexcom's DXCM.O over-the-counter continuous glucose monitor Stelo is ahead of Abbott's ABT.N Lingo
** Stelo is gaining traction benefitting from an earlier launch compared to Lingo - Citi
** Adds app datapoints to a recovery for Dexcom, after the glucose monitor maker slashed its annual revenue forecast
** Brokerage says downloads of apps for Dexcom's continuous glucose monitor G7 went up in August, setting a record high in downloads since launch, after a slower April, May and June with a slight uptick in July
** Adds U.S. downloads of apps for ABT's FreeStyle Libre 3seem to have struggled in May and June, with a stable July, followed by a more difficult August
** DXCM shares have fallen ~47%, while ABT up ~3% YTD
Reporting by Sriparna Roy in Bengaluru
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里。